htl0014242
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 14, 2018 (NCT03785054)
Timeline
Indications
Mechanism of action
GRIK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06648655 | Phase 2 | Dec 31, 2024 | Tempero Bio, Inc. |
| NCT06648668 | Phase 1 | Nov 15, 2024 | Tempero Bio, Inc. |
| NCT06025396 | Phase 1 | Jan 6, 2023 | National Institute on Drug Abuse (NIDA), Tempero Bio, Inc. |
| NCT04462263 | Phase 1 | Jun 29, 2020 | Heptares Therapeutics Limited |
| NCT03785054 | Phase 1 | Nov 14, 2018 | Covance, Heptares Therapeutics Limited |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Tempero Bio, Inc. | For profit | 3 | 3 | 2 | 2023 |
| Heptares Therapeutics Limited | For profit | 2 | 2 | 1 | 2018 |
| Covance | For profit | 1 | 0 | 1 | 2018 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1